Skip to main content

Exploring the TALAPRO-2 Study of Talazoparib and Enzalutamide in Prostate Cancer: Stephen Freedland, MD, and Neeraj Agarwal, MD

In this interview, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, speaks with Dr. Neeraj Agarwal, Director of the Genitourinary (GU) Medical Oncology Group at Huntsman Cancer Institute, about his recent publication of the TALAPRO-2 study. Dr. Agarwal delves into the results of the trial, which investigated the efficacy of talazoparib plus enzalutamide for first-line metastatic castration-resistant prostate cancer (mCRPC), and their practice-changing significance. 

Continue reading

Implementing Hepatic Artery Infusion Pump Programs With Sepideh Gholami, MD, MAS, FACS, FSSO

Oncology Data Advisor® · Implementing Hepatic Artery Infusion Pump Programs With Sepideh Gholami, MD, MAS, FACS, FSSO Recently, Sepideh Gholami implemented a Hepatic Artery Infusion Pump Program at Northwell Health. In this interview, Dr. Gholami discusses what exactly a hepatic artery infusion pump is, its benefits, and how it will affect the future treatment landscape of cancers as a whole. As well, she advocates for the implementation of these programs in more institutions across t...

Continue reading

Enzalutamide Approved for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD

The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, co-lead investigator of the trial, sat down to share more about its significance for patients with high-risk prostate cancer and biochemical recurrence.

Continue reading

Additional Advances in Advanced Prostate Cancer With Tanya Dorff, MD

Oncology Data Advisor® · Additional Advances in Advanced Prostate Cancer With Tanya Dorff, MD Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as additional ongoing and future clinical trials to...

Continue reading

Ivosidenib Approved for IDH1-Mutant Myelodysplastic Syndromes With Amir Fathi, MD

Recently, the FDA approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. In this interview, Amir Fathi, MD, Director of the Leukemia Program at Massachusetts General Hospital, one of the leaders of the AG120-C-001 trial (NCT02074839), on which approval was based, sat down to further discuss the trial and approval, as well as what this could mean for the future treatment landscape of MDS. &n...

Continue reading

Pancreatic Cancer Awareness Month: Improving Early Detection With Joseph Kalis, PharmD, BCOP

This November, Oncology Data Advisor is honoring Pancreatic Cancer Awareness Month and helping to raise awareness about early detection in hopes of improving outcomes for patients with this disease. In this interview, Oncology Data Advisor Editorial Board member Joseph Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, explains the challenges related to diagnosis and screening, ongoing efforts to develop better detection methods, and messages for both the public and the health care community for maintaining awareness of pancreatic cancer.  

Continue reading

Lung Cancer Awareness Month: Global Perspectives on Treatment and Equity With MedNews Week and Oncology Data Advisor

In this Lung Cancer Awareness Month video, members of Oncology Data Advisor and MedNews Week join forces to share global perspectives regarding treatment, equity, and patient advocacy in lung cancer.  

Continue reading

Great American Smokeout: The Link Between Smoking and Prostate Cancer With Stephen Freedland, MD

In honor of the Great American Smokeout, Oncology Data Advisor sat down with Stephen Freedland, MD, the Director of the Center for Integrated Research in Cancer and Lifestyle at Cedars-Sinai Medical Center, to discuss the impact that smoking has on prostate cancer, as well as to help raise awareness around smoking and share resources for those who are trying to quit.  

Continue reading

National Family Caregivers Month With Megan-Claire Chase

During National Family Caregivers Month this November, Oncology Data Advisor is celebrating the caregivers of patients with cancer and advocating for increased awareness, support, and education regarding the caregiving experience. In this interview, Megan-Claire Chase, patient advocate and member of the Oncology Data Advisor Editorial Board, shares her experience of being a caregiver for her mother, how her perception has changed before and after her own cancer diagnosis, the importance of prioritizing mental health, and messages for clinicians who seek to provide increased support for their patients' caregivers.  

Continue reading

National Family Caregivers Month: The Nurse's Perspective With Maria Badillo, MSN, RN, OCN®, CCRP

During National Family Caregivers Month this November, Oncology Data Advisor is spotlighting not only the caregivers of patients with cancer, but also the oncology nurses who partner with them to help navigate the cancer care journey. In this interview, Maria Badillo, Research Nurse Manager at MD Anderson Cancer Center and OncData Editorial Board member, shares how she helps support and provide education for her patients' caregivers, as well as resources she recommends for guiding them through the experience. 

Continue reading

Lung Cancer Awareness Month With Waqas Haque, MD, MPH; Samuel Kareff, MD, MPH; and Matthew Hadfield, DO

Oncology Data Advisor® · Lung Cancer Awareness Month With Waqas Haque, Samuel Kareff, & Matthew Hadfield On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Fellows Forum joined forces to share recent research in lung cancer diagnosis and screening, the need to address disparities experienced by patients, and ways to raise awareness for patients, the public, and the health care community throughout the month of November. Hear unique perspectives fro...

Continue reading

Venetoclax for Multiple Myeloma in the Post-CANOVA Era With Rahul Banerjee, MD, FACP, and Andrew Yee, MD

At the recent International Myeloma Society (IMS) Annual Meeting in Athens, Greece, results were presented of the CANOVA study of venetoclax for patients with relapsed/refractory multiple myeloma. After returning from the meeting, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and Oncology Data Advisor Editorial Board Member, and Dr. Andrew Yee, Clinical Director for Multiple Myeloma at Massachusetts General Hospital, sat down to reflect on the surprising results of the trial and its implications for the current and future treatment of patients with t(11;14) multiple myeloma.  

Continue reading

Additional Advances in Small Cell Lung Cancer Radiotherapy With Henry Park, MD, MPH

Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health's CME/NCPD/CPE–approved podcast, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC.  

Continue reading

Understanding the Tumor Microenvironment to Unlock the Key to Oncology Drug Development With Jesus Garcia, PhD

This interview features Jesus Garcia, PhD, a tissue and liquid biopsy expert who analyzes trial sponsors' clinical protocols and aids them in developing relevant biomarker strategies for their trials. Dr. Garcia discusses his passion for understanding the tumor microenvironment, its implications in drug development, and breakthrough strategies in pathology and technology that are leading to expanded therapeutic options for patients.  

Continue reading

Leveraging Community-Academic Partnerships to Improve Care for Latinx AYA Cancer Survivors With Stephanie Smith, MD

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephanie Smith, Pediatric Oncologist at Stanford Medicine, sat down with Oncology Data Advisor to discuss her research on leveraging community-academic partnerships to improve access to survivorship care for Latinx adolescent/young adult (AYA) cancer survivors. Dr. Smith explains the barriers faced by this population and the unique role that community cancer centers play in providing equitable care as patients transition into adult survivorship.  

Continue reading

Finding Real-World Response End Points in NSCLC Data Sets With Janet Espirito, PharmD

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Janet Espirito, PharmD, a Senior Medical Director at Ontada, sat down with Oncology Data Advisor to discuss her presentation on identifying real-world end points for assessing response in patients receiving novel therapies for metastatic non–small cell lung cancer (NSCLC) outside of clinical trials.  

Continue reading

Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD

Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With numerous developments in the field occurring since recording the activity, including new FDA approvals and clinical trial results, Dr. Leal sat down with Oncology Data Advisor to provide an update on the rapidly evolving field of NSCLC immunotherapy.  

Continue reading

Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Beth Sandy, MSN, CRNP

Oncology Data Advisor™ · Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials Just under a year ago, Beth Sandy, a Thoracic Oncology Nurse Practitioner, co-led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity, Harnessing Immunotherapy-Based Strategies For Advanced Non–Small Cell Lung Cancer (NSCLC). In this interview, she provides an update on advancements made in treatment and supportive care s...

Continue reading

Appendix Cancer Awareness Month With Thomas Abrams, MD

In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Harvard Medical School, sat down to explain the different subtypes and presentations of appendix cancer, factors he takes into consideration when making treatment decisions, and the messages he hopes to convey to both clinicians and patients with the goal of raising awareness for this rare disease.  

Continue reading

Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023 With Rahul Banerjee, MD, FACP, and Shonali Midha, MD

At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.  

Continue reading